• Company
• Can Koselugo pass the Pharmaceutical Evaluation Committee?
• by Eo, Yun-Ho Sep 4, 2023 05:04am

• Company
• Enhertu posts KRW 7.4 bil in H1 sales without reimb
• by Kim, Jin-Gu Sep 1, 2023 05:44am

• Policy
• Kanoa, the upper limit price was reduced further by PVA
• by Lee, Tak-Sun Sep 1, 2023 05:44am

• Policy
• MOHW ‘is discussing expanding non-face-to-face treatment’
• by Lee, Jeong-Hwan Sep 1, 2023 05:44am

• Company
• Two targeted anticancer therapies fail reimb in KOR
• by Eo, Yun-Ho Sep 1, 2023 05:44am

• Policy
• The 1st results of the pharmaceutical benefit re-evaluation
• by Lee, Tak-Sun Sep 1, 2023 05:43am

• Company
• Released next-generation growth hormone drug
• by Kim, Jin-Gu Aug 31, 2023 05:25am

• Policy
• Cold medicine bills increased by 90% due to the coronavirus
• by Lee, Tak-Sun Aug 31, 2023 05:25am

• Company
• Hemophilia drug Hemlibra’s sales rise twofold with reimb
• by Chon, Seung-Hyun Aug 31, 2023 05:25am

• Company
• The obesity market doubled in 5 years
• by Chon, Seung-Hyun Aug 31, 2023 05:25am